Clopidogrel
Product Images NDC 51407-032

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 51407-032). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407 032 30lb

Clopidogrel 75 mg tablets, USP, packaging label from Golden State Medical Supply, Inc. The label indicates 30 tablets per container, Rx Only, with the product NDC 51407-032-30. It provides information on dosage form, strength, and storage conditions, including protection from moisture and recommended storage temperature. Manufactured by Apotex Inc and marketed by GSMS, Incorporated.*

FDA Label Image

Figure3.jpg (Figure3)

A forest plot titled 'Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study.' It compares hazard ratios with 95% confidence intervals for Clopidogrel versus placebo across various patient subgroups including age, gender, race, enzyme elevation, diabetes status, previous myocardial infarction, and previous stroke. The plot visually displays the favorability towards Clopidogrel or placebo for each subgroup and overall outcomes.*

FDA Label Image

Figure3b.jpg (Figure3b)

A forest plot figure showing hazard ratios with 95% confidence intervals for patient baseline characteristics and concomitant medications in the CURE Study. It compares subgroups based on Heparin/LMWH, Aspirin dosage, GPIIb/IIIa Antagonist, Beta-Blocker, and Ace Inhibitor use, illustrating risk differences favoring Clopidogrel or placebo across these variables.*

FDA Label Image

Figure6.jpg (Figure6)

A forest plot illustrating the effects of adding Clopidogrel to Aspirin on the combined primary endpoint across various baseline and concomitant medication subgroups from the COMMIT Study. The chart displays odds ratios with 99% confidence intervals for subgroups categorized by gender, age, time since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, comparing Clopidogrel and placebo outcomes.*

FDA Label Image

Figure7.jpg (Figure7)

A line graph titled 'Fatal or Non-Fatal Vascular Events in the CAPRIE Study' comparing cumulative event rates (%) over months of follow-up between Clopidogrel and Aspirin. The x-axis shows months from 0 to 36, and the y-axis shows cumulative event rates from 0 to 18%. Clopidogrel shows a slightly lower cumulative event rate compared to Aspirin over time, with a p-value of 0.045 indicated on the graph.*

FDA Label Image

Figure8.jpg (Figure8)

The figure is a forest plot titled 'Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study' comparing Clopidogrel and Aspirin across three qualifying conditions: Stroke, MI, and PAD. It displays counts and percentages for each treatment group and indicates hazard ratios with 95% confidence intervals, showing comparative favorability between Clopidogrel and Aspirin.*

FDA Label Image

Figure-01.jpg (Figure 01)

A figure titled 'Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel 75 mg Alone or with Proton Pump Inhibitors (PPIs)', displaying the effect on active metabolite AUC with mean and 90% confidence intervals. It compares co-administration of four PPIs (Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, Omeprazole 80 mg) relative to Clopidogrel alone, with a horizontal axis showing change relative to Clopidogrel administered alone from 0.4 to 1.4.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph comparing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up between placebo plus aspirin and clopidogrel plus aspirin groups in the CURE study. The graph shows lower event rates for the clopidogrel plus aspirin group compared to placebo plus aspirin, with a p-value of 0.00009 indicating statistical significance.*

FDA Label Image

Figure4.jpg (Figure4)

A cumulative event rate graph showing the percentage of deaths before first discharge over up to 28 days since randomization in the COMMIT Study. It compares two groups: Placebo with 8.1% deaths and Clopidogrel with 7.5% deaths, indicating a 7% proportional risk reduction (p=0.03). The y-axis is labeled '% dead before first discharge' and the x-axis labeled 'Days since randomization (up to 28 days)'.*

FDA Label Image

Figure5.jpg (Figure5)

A cumulative event rates graph from the COMMIT study showing the combined endpoint of re-infarction, stroke, or death over 28 days. The y-axis represents the percentage of patients with events before first discharge, while the x-axis shows days post-randomization. Two lines compare placebo (10.1% events) and Clopidogrel (9.2% events) groups, indicating a 9% proportional risk reduction for Clopidogrel. All patients also received aspirin.*

FDA Label Image

Image100

Chemical structure of Clopidogrel shown with labeled atoms and bonds including sulfur, nitrogen, chlorine, and carbon groups along with a sulfate (H2SO4) molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.